This is also a textbook case of what is seen vs. what is unseen. When someone dies from a treatment that the FDA has approved, that is a visible ("seen") tragedy. When people are suffering from ailments that could be treated more effectively if not for the FDA slowing things down and raising the cost of development, that is unseen. There's no single victim you can point to. But the latter is hard to quantify in the risk vs. reward calculation, and importantly no FDA bureaucrat will ever lose their job or be publicly shamed because of them.